What XTL Biopharmaceuticals does

XTL Biopharmaceuticals Ltd. is a pre-commercial, clinical-stage biopharmaceutical company incorporated in Israel and publicly traded on NASDAQ (XTLB) and the Tel Aviv Stock Exchange. Founded in 1993 and public since 2000, the company historically focused on acquiring and developing late-stage pharmaceutical candidates for unmet clinical needs, with two core pipeline assets: hCDR1, a novel peptide for Systemic Lupus Erythematosus that has completed three clinical trials involving more than 400 patients with a favorable safety profile; and Recombinant Human Erythropoietin (rHuEPO), which received FDA Orphan Drug Designation in 2011 for advanced Multiple Myeloma. hCDR1's mechanism of action involves upstream immunomodulation via regulatory T cell generation, distinct from conventional immune-suppressing therapies.

In 2024-2026, XTL executed a strategic pivot through three acquisitions: The Social Proxy (AI web data, March 2024 — subsequently court-ordered liquidated February 2026); NeuroNOS (85% stake, January 2026 — adding autism spectrum disorder and neuro-oncology therapeutics with two FDA Orphan Drug Designations); and Psyga Bio (April 2026 — adding psychedelic and functional mushroom-derived therapeutics with 180+ proprietary mushroom strains and seven Phase 2a trials). The company has no commercial products and generates no product revenue, with anticipated future revenue from licensing, co-development partnerships, or eventual commercial sales.

The company faces acute financial and regulatory distress: stockholders' equity deficit of -$47,000 as of June 2025, market capitalization of approximately $5.9-9.36 million, Nasdaq public shell classification, two delisting determinations, a reverse ADS ratio change (1:100 to 1:400) in March 2026, and significant equity dilution with Beyond Air Inc. retaining 19.99% post-NeuroNOS and Psyga Bio shareholders receiving 40% of share capital. Headcount is 1-10 employees.

Name

XTL Biopharmaceuticals

Legal name

XTL Biopharmaceuticals Ltd.

Website

https://xtlbio.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

1–10 employees

Short description

XTL Biopharmaceuticals is a pre-commercial, clinical-stage Israeli biopharmaceutical company developing late-stage therapeutics for autoimmune disease, multiple myeloma, autism spectrum disorder, and psychedelic-derived neurological conditions, with no commercial products and significant financial distress.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

Keywords

• Drug development pipeline
• Novel peptide therapeutics
• Recombinant biologics
• Orphan drug candidates
• Clinical stage biopharmaceuticals

Headquarters

HQ city

Herzliya

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Distribution channels1 record

Marketing channels3 records

Core offering

XTL Biopharmaceuticals Ltd. acquires and develops late-stage proprietary pharmaceutical product candidates targeting unmet clinical needs. Its current pipeline includes hCDR1, a novel peptide for Systemic Lupus Erythematosus that has completed Phase I/II trials in more than 400 patients, and Recombinant Human Erythropoietin (rHuEPO), a biologic granted FDA orphan drug designation for advanced Multiple Myeloma. Through 2026 acquisitions of NeuroNOS and Psyga Bio, XTL also develops therapeutics for Autism Spectrum Disorder, neuro-oncology, and CNS indications including psychedelic and functional mushroom-derived compounds.

Product overview

XTL Biopharmaceuticals is a pharmaceutical company focused on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for unmet clinical needs. The company operates two core product candidates: hCDR1 peptide for Systemic Lupus Erythematosus and Recombinant Human Erythropoietin (rHuEPO) for Multiple Myeloma. The company has also pursued strategic acquisitions including NeuroNOS (85% ownership) for autism and neuro-oncology therapeutics, and previously The Social Proxy (now insolvent) for AI web data technology.

Differentiator

Problem solved

Functional benefit

Products and services

• hCDR1 (Edratide) peptide A novel peptide compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE), generating regulatory T cells that beneficially modulate auto-reactive T and B cells, autoantibodies, and pathogenic cytokines. Has completed three clinical trials involving more than 400 patients and demonstrated a favorable safety profile.
• Recombinant Human Erythropoietin (rHuEPO) A known anemia agent being developed to prolong survival and improve quality of life of patients with advanced Multiple Myeloma. Granted FDA orphan drug designation in 2011. Has demonstrated anti-myeloma effects through immune-mediated mechanisms likely mediated via T cells, dendritic cells, and macrophages.
• NeuroNOS disease-modifying therapeutics Disease-modifying therapeutics targeting the core pathophysiology of Autism Spectrum Disorder and neuro-oncology. Holds two FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma. Backed by Nobel Prize-winning scientific leadership from Professors Dan Shechtman and Roger Kornberg.
• Psyga Bio psychedelic and functional mushroom-derived therapeutics Therapeutic pipeline backed by a proprietary library of more than 180 unique mushroom strains for psychedelic and functional mushroom-derived therapeutics. Operates a GMP-ready pharmaceutical manufacturing facility. Seven planned Phase 2a clinical trials target mental health, addiction, and neurological conditions.

Quantifiable outcome

• hCDR1 demonstrated favorable safety profile in Phase I and Phase II trials with over 400 patients
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Psyga Bio Ltd.coreStrategic or Co-development Partner · 29 April 2026XTL entered into a definitive share purchase agreement to acquire 100% of Psyga Bio, an advanced biotechnology company focused on psychedelic and functional mushroom-derived therapeutics. Psyga operates a licensed GMP-ready pharmaceutical manufacturing facility and holds a proprietary library of over 180 unique mushroom strains. Seven Phase 2a human clinical trials expected to commence soon across mental health, addiction, and neurological conditions. Transaction structured with milestone-based earnout provisions entitling Psyga shareholders to additional equity upon achievement of milestones.
• Beyond Air Inc.coreStrategic or Co-development Partner · 13 February 2026Beyond Air completed divestiture of its NeuroNOS subsidiary to XTL Biopharmaceuticals, retaining 19.9% equity stake and up to $31.5 million in potential milestones. This strategic transaction enables XTL to enter the autism market with disease-modifying therapeutics.
• NeuroNOS Ltd. (subsidiary of Beyond Air Inc.)coreStrategic or Co-development Partner · 13 January 2026XTL acquired 85% of NeuroNOS, a biotech subsidiary developing disease-modifying therapeutics for Autism Spectrum Disorder and neuro-oncology. Transaction included 19.9% of XTL's share capital, $1 million in cash, and milestone-based payments of up to $32.5 million. Beyond Air retained 19.99% stake post-transaction. NeuroNOS holds two FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, with Nobel Prize-winning scientific leadership.
• The Social Proxy Ltd.minorStrategic or Co-development Partner · 20 March 2024XTL acquired The Social Proxy, an AI web data company, for $430,000 in cash and share issuance plus warrants contingent on future milestones. The Social Proxy operated as a wholly owned subsidiary of XTL until it filed for insolvency proceedings in January 2026 and was subsequently liquidated by court order in February 2026.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• BioLineRx: Israel-based, clinical-stage biopharmaceutical company developing late-stage assets for unmet medical needs. Comparable in size, stage, and Israeli/dual-listed (NASDAQ/TASE) profile with similarly narrow pipelines.
• RedHill Biopharma: Israeli specialty biopharma focused on late-stage drug development and commercialization, with a similar small-cap, NASDAQ/TASE-listed profile and emphasis on in-licensing and developing differentiated therapeutics.
• Can-Fite BioPharma: Israel-based clinical-stage biotech developing small-molecule therapeutics for autoimmune/inflammatory diseases and oncology. Most directly comparable to XTL's autoimmune (lupus) and oncology (multiple myeloma) programs.
• Protalix BioTherapeutics: Israel-based biopharmaceutical company developing recombinant therapeutic proteins using proprietary expression systems. Comparable as a small-cap Israeli biotech developing recombinant biologics like XTL's rHuEPO program.
• Compugen: Israel-based clinical-stage biotech leveraging computational platforms for therapeutic discovery in immuno-oncology. Comparable Israeli small-cap profile with NASDAQ/TASE dual listing and clinical-stage pipeline.
• Galmed Pharmaceuticals: Israel-based clinical-stage biopharmaceutical company developing therapeutics for liver diseases. Comparable small-cap Israeli NASDAQ/TASE-listed biopharma with single-asset clinical focus.
• UroGen Pharma: Specialty pharmaceutical company developing therapeutics for urological and specialty oncology indications with multiple Orphan Drug Designations. Comparable small-cap profile with regulatory exclusivity-driven pipeline strategy.
• ProQR Therapeutics: Clinical-stage biotech developing RNA therapies for rare diseases. Comparable small-cap clinical-stage rare-disease biotech with similar reliance on Orphan Drug pathways and milestone-based out-licensing economics.

Broad incumbents

• Beyond Air: Parent company that divested NeuroNOS to XTL, retaining a 19.99% stake. Relevant comparable as a small-cap medical/biotech NASDAQ-listed company that originated the autism/neuro-oncology platform now held by XTL.
• Teva Pharmaceutical Industries: Israel-headquartered global pharmaceutical giant and former employer of XTL's ex-CEO (Joshua Levine). Provides broader Israeli pharma industry context and potential licensing/out-licensing counterparty for XTL's pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/xtl-biopharmaceuticals-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XTL Biopharmaceuticals